The Cooper Companies, Inc. (COO)

How it makes money

The lens business is a recurring-purchase model: contact lenses wear out and are reordered regularly, so once a patient is fitted with a brand, replacement sales tend to continue for years. The surgical and fertility business instead sells instruments, disposable devices and lab equipment to clinics and hospitals — some of it capital equipment bought once, some of it consumables reordered with each procedure. Growth in each half of the company depends on different things: population trends in vision correction for one, and clinic capacity and IVF cycle volumes for the other.

Revenue by segment

A patient fitted and comfortable with a specific contact lens rarely switches brands on their own initiative, and an eye-care professional who has standardized on a fitting set has a mild reason to keep prescribing it. Neither habit is unbreakable: a competing lens of similar quality, or a clinic's own procurement decision, can still displace it.

Vision correction is an ongoing need regardless of the economy, which supports the lens business through downturns. The fertility side is more sensitive to discretionary spending and to clinics' own capital budgets: equipment purchases can be postponed when clinics turn cautious, even if underlying procedure demand holds up.

Key risks

• Competition from larger diversified companies — In women's health and fertility, CooperSurgical competes against much larger medical-device companies with broader product lines and greater resources, which can give them an edge in marketing and bundled deals.
• Reimbursement and pricing pressure — Changes in third-party coverage and reimbursement, and pricing pressure from competitors, can reduce demand or margins on both contact lenses and medical devices.
• Clinic capital spending cycles — Fertility clinics have shown caution in equipment purchases in soft periods, which slows CooperSurgical's capital-equipment sales even when procedure volumes are stable.